Trading Signals: SAGE Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Fri. Dec. 22, 2023)(SAGE Therapeutics Inc)
| SAGE latest price $45.0050 (-3.98%) ($44.8500 - $45.0050) on Tue. Sep. 28, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 2.51% (three month average) | RSI | 47 | Latest Price | $45.0050(-3.98%) | Stocks Behave Similarly | Similar Stock List | Weekly Trend | SAGE advances 0.1% a week on average for past two weeks. | Market Behavior | Broad based sell-off for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support SAGE advance at 0% a week (0% probability) IBB(50%) IWO(44%) IWC(43%) IWM(42%) IWN(37%) | Factors Impacting SAGE price | SAGE will decline at least -1.255% in a week (0% probabilities). VIXM(-28%) UUP(-12%) VXX(-7%) TBT(-2%) UNG(-1%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.255% (StdDev 2.51%) | Hourly BBV | -0.7 () | Intraday Trend | 0% | | | |
|
Resistance Level | $45.45 | 5 Day Moving Average | $45.35(-0.76%) | 10 Day Moving Average | $45.16(-0.34%) | 20 Day Moving Average | $45.45(-0.98%) | To recent high | -21.7% | To recent low | 11.9% | Market Cap | $2.337b | | | | SAGE Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel medicines to treat life-altering central nervous system. Its programs include brexanolone, which is an acute interventional treatment for postpartum depression; and SAGE-217, an oral therapy for treatment of various CNS disorders. The company was founded by Steven Marc Paul and Douglas Covey in April 2010 and is headquartered in Cambridge, MA. |